.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Predict branded drug patent expiration
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Cantor Fitzgerald
McKesson
Accenture
Chinese Patent Office
Merck
Covington
Chubb
Baxter
Julphar

Generated: June 28, 2017

DrugPatentWatch Database Preview

OTIPRIO Drug Profile

« Back to Dashboard

Which patents cover Otiprio, and what generic Otiprio alternatives are available?

Otiprio is a drug marketed by Otonomy Inc and is included in one NDA. There are four patents protecting this drug.

This drug has one hundred and twenty-one patent family members in eighteen countries.

The generic ingredient in OTIPRIO is ciprofloxacin. There are thirty-one drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the ciprofloxacin profile page.

Summary for Tradename: OTIPRIO

Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list71
Clinical Trials: see list3
Patent Applications: see list6,800
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:OTIPRIO at DailyMed

Pharmacology for Tradename: OTIPRIO

Ingredient-typeQuinolones
Drug ClassQuinolone Antimicrobial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Otonomy Inc
OTIPRIO
ciprofloxacin
INJECTABLE, SUSPENSION;OTIC207986-001Dec 10, 2015RXYesYes9,233,068► SubscribeY ► Subscribe
Otonomy Inc
OTIPRIO
ciprofloxacin
INJECTABLE, SUSPENSION;OTIC207986-001Dec 10, 2015RXYesYes9,205,048► Subscribe ► Subscribe
Otonomy Inc
OTIPRIO
ciprofloxacin
INJECTABLE, SUSPENSION;OTIC207986-001Dec 10, 2015RXYesYes9,220,796► SubscribeY ► Subscribe
Otonomy Inc
OTIPRIO
ciprofloxacin
INJECTABLE, SUSPENSION;OTIC207986-001Dec 10, 2015RXYesYes8,318,817► Subscribe ► Subscribe
Otonomy Inc
OTIPRIO
ciprofloxacin
INJECTABLE, SUSPENSION;OTIC207986-001Dec 10, 2015RXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: OTIPRIO

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,852,626Controlled-release CNS modulating compositions and methods for the treatment of otic disorders► Subscribe
9,066,855Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders► Subscribe
8,496,957Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders► Subscribe
8,784,870Controlled release compositions for modulating free-radical induced damage and methods of use thereof► Subscribe
8,575,122Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: OTIPRIO

Country Document Number Estimated Expiration
Japan2014101392► Subscribe
China102112112► Subscribe
South Korea101390607► Subscribe
South Korea101534422► Subscribe
Japan2011518195► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: OTIPRIO

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB12/058United Kingdom► SubscribePRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
C0012France► SubscribePRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
US Department of Justice
Express Scripts
Baxter
US Army
McKesson
Fish and Richardson
McKinsey
Chubb
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot